QSAM Biosciences Activates Clinical Sites and Opens Enrollment for Its Phase I Clinical Trial of CycloSam^® for the Treatment of Bone Cancer

QSAM Biosciences, Inc. announced the activation of its first clinical trial site and the initiation of enrollment of patients into its Phase I clinical trial evaluating CycloSam® for multiple types of bone cancer that either originated in or has metastasized to the bone.